Initiation report from the analyst Edison Group

AMOEBA announces initiation report from the analyst Edison Group

Lyon (France), March 13th, 2023 – 17:45 – AMOÉBA (FR0011051598 – ALMIB), an industrial biotech in pre-commercialization* specializing in the treatment of microbiological risk, developing a biocontrol agent for the treatment of plants in agriculture and a biological biocide for the treatment of industrial water, announces that Edison Group, a London-based equity research house, has initiated coverage on the company. 

This research contract, financed by the company, aims to allow investors to broaden their understanding of the company, which is necessary to take a position on Amoéba shares (ALMIB).

The first note, entitled “Amoéba, fighting pathogens, respecting nature” is available to all investors and provides insight into the business’ plans to raise €45m to fund its operations and expand its site over the next three years. Subsequent research will keep shareholders up to date with Amoeba’s finances, strategy and operational progress.  

The company informs that, as Amoéba plans to double the size of its biocontrol plant in Cavaillon in 2027, Edison Group’s estimations on this first note are based on a production capacity allowing the treatment of 200 000 hectares.

Edison’s research is available on Amoéba’s website in the “Shareholding / Coverage” section as well as directly from the Edison website and via major financial data providers including Bloomberg.